Table 3.
Clinical characteristics of patients living ≥ 5 and < 5 years n (%)
| Items | Total (n) |
Patients living |
t/χ2 | P value | |
| ≥ 5 yr | < 5 yr | ||||
| 209 | 81 (38.8) | 128 (61.2) | |||
| Sex | 0.367 | 0.545 | |||
| Male | 121 | 49 (60.5) | 72 (56.2) | ||
| Female | 88 | 32 (39.5) | 56 (43.8) | ||
| Age (mean ± SD, yr) | 49.2 ± 4 | 47.8 ± 8 | 2.868 | 0.488 | |
| Child-Pugh score | 6.888 | 0.032 (P < 0.05) | |||
| A | 83 | 38 (46.9) | 45 (35.2) | ||
| B | 72 | 30 (37.0) | 42 (32.8) | ||
| C | 54 | 13 (16.1) | 41 (32.0) | ||
| PVTT | 10.249 | 0.001 (P < 0.05) | |||
| With | 31 | 4 (4.9) | 27 (21.1) | ||
| Without | 178 | 77 (95.1) | 101 (78.9) | ||
| Lesion number | 0.263 | 0.608 | |||
| Single | 148 | 59 (72.8) | 89 (69.5) | ||
| Multiple | 61 | 22 (27.2) | 39 (30.5) | ||
| Lesion diameter | 18.351 | 0.0001 (P < 0.05) | |||
| ≤ 3 cm | 52 | 27 (33.3) | 25 (19.5) | ||
| > 3, ≤ 5 cm | 103 | 46 (56.8) | 57 (44.6) | ||
| > 5 cm | 54 | 8 (9.9) | 46 (35.9) | ||
| Hepatic arterio-portal fistulas | 6.537 | 0.011 (P < 0.05) | |||
| With | 22 | 3 (3.7) | 19 (14.8) | ||
| Without | 187 | 78 (96.3) | 109 (85.2) | ||
| Cancer diagnosed | 5.973 | 0.015 (P < 0.05) | |||
| Pre-TIPS | 142 | 47 (58.0) | 95 (74.2) | ||
| Post-TIPS | 67 | 34 (42.0) | 33 (25.8) | ||
| Stents | 4.446 | 0.035 (P < 0.05) | |||
| Bare stent | 112 | 36 (44.4) | 76 (59.4) | ||
| Covered stent | 97 | 45 (55.6) | 52 (40.6) | ||
| Recurrence (ascites/bleeding) | 3.624 | 0.057 | |||
| Yes | 92 | 29 (25.8) | 63 (49.2) | ||
| No | 117 | 52 (64.2) | 65 (50.8) | ||
| Hepatic encephalopathy | 3.887 | 0.049 (P < 0.05) | |||
| Yes | 82 | 25 (30.9) | 57 (44.5) | ||
| No | 127 | 56 (69.1) | 71 (55.5) | ||
| Interventional therapy | 7.556 | 0.023 (P < 0.05) | |||
| RFA | 24 | 13 (16.0) | 11 (8.6) | ||
| TACE/TAE | 96 | 28 (34.6) | 68 (53.1) | ||
| RFA + TACE/TAE | 89 | 40 (49.4) | 49 (38.3) | ||
| Distributary channel function | 3.274 | 0.070 | |||
| Restenosis | 122 | 41 (50.6) | 81 (63.3) | ||
| Unobstructed | 87 | 40 (49.4) | 47 (36.7) | ||
PVTT: Portal vein tumor thrombosis; TIPS: Transjugular intrahepatic portosystemic shunt; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; RFA: Radiofrequency ablation.